Aquestive therapeutics announces $75m strategic funding agreement with rtw to support the potential launch of anaphylm™ (epinephrine) sublingual film

Warren, n.j., aug. 14, 2025 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive” or the “company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by rtw investments, lp (“rtw”), subject to united states food and drug administration (fda) approval of anaphylm™ (epinephrine) sublingual film and other conditions.
AQST Ratings Summary
AQST Quant Ranking